Percutaneous MR-Guided Cryoablation of Low-Flow Vascular Malformation: Technical Feasibility, Safety and Clinical Efficacy
Authors:
- Pierre-Alexis AutrusseauPAPierre-Alexis Autrusseau
- Roberto Luigi CazzatoRCRoberto Luigi Cazzato
- Pierre De MariniPMPierre De Marini
- Danoob DaliliDDDanoob Dalili
- Guillaume KochGKGuillaume Koch
- Emanuele BoattaEBEmanuele Boatta
- Pierre AulogePAPierre Auloge
- Julien GarnonJGJulien Garnon
- Afshin GangiAGAfshin Gangi
- 31 March 2020
- journal article
- research article
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (6) , 858-865
Abstract
Purpose To retrospectively assess the technical feasibility, safety and clinical efficacy of percutaneous MR-guided cryoablation of low-flow vascular malformations (LFVM). Materials and Methods Between July 2013 and May 2019, 9 consecutive patients (5 male; 4 female; mean age 39.4 ± 15.3 years, range 15–68) underwent MR-guided cryoablation of LFVM. Patients were treated due to pain in all cases. Procedural data, complications and clinical results were analyzed. Results Technical success defined as complete coverage of the LFVM by the iceball without involvement of nearby non-target thermal-sensitive structures was achieved in 9/9 (100%) cases. Mean procedure time was 122 ± 20 min (range 90–150); 2–6 cryoprobes (mean 3.7 ± 1.2) and 2–4 freezing cycles (mean freezing time 19.8 ± 11.8 min; range 4–40) were applied. No complications were noted. Mean time from the first treatment to the last follow-up was 548 days (range 30–1776). Persistent/recurring pain was noted in 3/9 cases (33%) 30, 133 and 639 days after cryoablation, respectively, and was related in all cases to MR-confirmed local residual/recurring disease. A second cryoablation treatment was performed in these 3 cases with complete pain control at the last available follow-up (153, 25, 91 days, respectively). In the whole population, at mean 161 days (range 25–413) after the last treatment, on the numerical pain rate scale, pain significantly dropped from mean 6.4 ± 2.1 (range 3–9/10) before CA to mean 0.3 ± 0.9 (range 0–3/10) after (p = 0.009). Conclusions Percutaneous MR-guided cryoablation is technically feasible, safe and effective for the treatment of symptomatic LFVM. Level of Evidence Level 3b, retrospective cohort study.Keywords
This publication has 17 references indexed in Scilit:
- Evidence-Based Management of Vascular MalformationsFacial Plastic Surgery, 2016
- Cryoablation in fibro-adipose vascular anomaly (FAVA): a minimally invasive treatment optionPediatric Radiology, 2016
- Vascular Malformations and Their Treatment in the Growing PatientOral and Maxillofacial Surgery Clinics of North America, 2016
- Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular AnomaliesPediatrics, 2015
- Initial Results of Image-Guided Percutaneous Ablation as Second-Line Treatment for Symptomatic Vascular AnomaliesCardioVascular and Interventional Radiology, 2015
- Sclerotherapy in venous malformationPhlebology: The Journal of Venous Disease, 2013
- Successful Treatment of Intramuscular Venous Malformation with Image-guided Radiofrequency AblationJournal of Vascular and Interventional Radiology, 2012
- Interventional Management of Vascular MalformationsTechniques in Vascular and Interventional Radiology, 2011
- Venous Malformations: Classification, Development, Diagnosis, and Interventional Radiologic ManagementRadiologic Clinics of North America, 2008
- Magnetic resonance of vascular anomaliesMagnetic Resonance Imaging Clinics of North America, 2002